We are
Helius
Medical.

Helius is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

The Pioneers of Portable
Neurostimulation
Pushing treatment options to rehabilitate lost function into the future
Solutions Backed
by Science
Dedicating years of research to ensure safety and efficacy
Enhancing the
Human Experience
Empowering individuals with neurological disorders and traumatic brain injury (mmTBI) by increasing their independence and quality of life
Real Patients with
Real Results*
“PoNS Therapy™ enabled me to improve my walking. Some tasks seem easier, which make my daily life better.”
Helius Medical Technologies Logo

We are
Helius
Medical.

Helius is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

Our Origin

Helius’ origin stems from the early 1990s, and the pioneering work in neuroplasticity at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison. This work led to the development of the investigational Portable Neuromodulation Stimulator (PoNS®), that delivers neurostimulation via the tongue, which has been shown in clinical studies to improve the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury.

Helius News

-- Q4 2022 revenue projected to range from $275,000 to $285,000 -- -- Full year 2022 revenue projected to range from $780,000 to $790,000 -- -- Unaudited year end cash balance of $14.5 million -- NEWTOWN, Pa., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc.

January 23, 2023

NEWTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer,

January 19, 2023

-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS ® therapy for gait improvement in Multiple Sclerosis -- NEWTOWN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Helius Medical

January 10, 2023

PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans NEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator (PoNS ® ) into the hands of qualified

January 5, 2023

Careers at Helius Medical

At Helius, you can have a positive impact on the lives of millions of people around the globe who rely on our innovations for their recovery. Helius brings together the world’s best talent to succeed in our ongoing mission. Together, we work passionately to develop and deliver easy-to-use technology for neurological wellness. If you want to join us in our mission, we want to hear from you.